Side-by-side · Research reference
TesofensinevsTestagen
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
APhase 3AUTO-DRAFTED10/40 cited
BAnimal-MechanisticHUMAN-REVIEWED11/41 cited
Tesofensine
SNDRI · Phase 3 obesity candidate
Oral · Once daily morning
Testagen
Bioregulator Peptide · Khavinson School
SQ · Abdomen · Cyclical
01Mechanism of Action
Parameter
Tesofensine
Testagen
Primary target
Serotonin / norepinephrine / dopamine transporters (SERT / NET / DAT)Astrup 2008
Testicular tissue; proposed nuclear DNA interaction
Pathway
Triple monoamine reuptake inhibition → ↑synaptic 5-HT, NE, DA → appetite suppression + thermogenesisAstrup 2008
Nuclear penetration → DNA/oligonucleotide binding → gene expression modulation (bioregulator hypothesis)Fedoreyeva 2011
Downstream effect
Strong appetite suppression, mild thermogenic effect, weight lossAstrup 2008
Proposed support for spermatogenesis and testicular function; mechanistic data limited to nuclear localization and DNA interactionFedoreyeva 2011
Feedback intact?
—
Unknown — no HPG axis data
Origin
Small molecule developed by NeuroSearch (Denmark) for CNS indications, repurposed for obesityAstrup 2008
Khavinson bioregulator school — isolated from testicular tissue peptide fractions
Antibody development
—
—
02Dosage Protocols
Parameter
Tesofensine
Testagen
Frequency
Once daily, morning
Once daily or alternate days
Lower / starter dose
0.125 mg / day
—
Evidence basis
Phase 2b + ongoing Phase 3Astrup 2008
Animal mechanistic / in vitro onlyFedoreyeva 2011
Duration
24 weeks per studied cycle
—
Form
Oral capsule
—
Timing
Morning to avoid sleep disruption
—
Half-life
~9 days (very long)
Unknown — likely minutes (short peptide)
Typical protocol (anecdotal)
—
100–200 mcg / day
No published human dosing studies; derived from Russian bioregulator practice.
Cycle length
—
10–20 days on, 10–14 days off
Bioregulator tradition uses pulsed cycles; no controlled data.
Route
—
Subcutaneous
Reconstitution
—
Sterile water or bacteriostatic saline
04Side Effects & Safety
Parameter
Tesofensine
Testagen
Insomnia
Dose-related; mitigate with morning timing
—
Dry mouth
Common
—
Nausea
Common
—
Mood changes
Anxiety / agitation possible
—
Cardiovascular events
Phase 3 trial monitoring; not yet FDA-cleared
—
Pregnancy / OB
Contraindicated
—
Injection site reactions
—
Erythema, mild irritation (potential)
Systemic effects
—
Unknown — no human safety data
Hormonal impact
—
No published data on testosterone, LH, FSH effects
Long-term safety
—
Unknown — no long-term studies
Absolute Contraindications
Tesofensine
- ·Pregnancy / breastfeeding
- ·Severe cardiovascular disease
- ·Concurrent MAOI use
Testagen
- ·Active testicular malignancy
Relative Contraindications
Tesofensine
- ·Hypertension
- ·Anxiety disorder
- ·Insomnia
Testagen
- ·Hormone-sensitive cancers (no data; theoretical caution)
- ·Pregnant or breastfeeding (no data)
05Administration Protocol
Parameter
Tesofensine
Testagen
1. Form
Oral capsule (investigational; not commercial).
Add 1–2 mL sterile or bacteriostatic water to lyophilised vial. Swirl gently; do not shake. Solution should be clear.
2. Administration
Swallow whole with water, morning only.
Subcutaneous — abdomen or thigh. Rotate sites daily. Use standard insulin syringe (27–31G).
3. Timing
Morning to mitigate insomnia. Do not dose evening.
Morning or evening; no established optimal timing. Anecdotal preference: evening to align with circadian testosterone patterns.
4. Storage
Room temp ≤25 °C, dry place.
Lyophilised: room temp, dark. Reconstituted: refrigerate 2–8 °C, use within 14–21 days if bacteriostatic water used.
5. Caveat
Monitor BP + HR + mood. Avoid stimulants + MAOIs.
10–20 days on, 10–14 days off. Bioregulator tradition uses pulsed exposure; rationale: prevent receptor/pathway desensitisation.